ExpressPoints
Cancer Conversations™: Experts Discuss and Debate Optimal Treatment of Relapsed/Refractory Multiple Myeloma

Gain key clinical insights fast, with this short slideset from CCO summarizing current and emerging treatment options for patients with relapsed or refractory myeloma.
Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 501 KB
Released: March 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides

Related Content

Download this short slideset on current optimal therapy for patients with AML from Clinical Care Options (CCO)

Amir T. Fathi, MD Daniel Pollyea, MD, MS Eunice S. Wang, MD Released: June 23, 2021

Gain key clinical insights from Paul G. Richardson with this slideset from CCO on treating patients with MM with relapse after first line therapy.

Paul G. Richardson, MD Released: June 23, 2021

Gain key insights on the latest available evidence quickly from this short slideset on the role of BTK inhibitors in CLL, from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Paolo Ghia, MD, PhD Veronique Leblond, MD Released: June 23, 2021

Downloadable slideset from ICML 2021 on the combination of BTK inhibitors in frontline CLL, from Clinical Care Options (CCO)

Veronique Leblond, MD Released: June 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue